Sugi Predict

Sugi Predict / Compounds / SCHEMBL13695658

SCHEMBL13695658

SCHEMBL13695658

CCC(CC)n1cc(-c2ncnc3[nH]ccc23)cn1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 20/20 0.69
▸ JAK1 P23458 12/20 0.69
▸ JAK3 P52333 8/20 0.57
▸ HDAC6 Q9UBN7 8/20 0.57
▸ TYK2 P29597 6/20 0.57
▸ RET P07949 3/20 0.57
▸ ROCK1 Q13464 3/20 0.57
▸ DAPK3 O43293 2/20 0.57
▸ PAK4 O96013 2/20 0.57
▸ ABL1 P00519 2/20 0.57
▸ LTK P29376 2/20 0.57
▸ CSNK1A1 P48729 2/20 0.57
▸ CLK2 P49760 2/20 0.57
▸ TNK2 Q07912 2/20 0.57
▸ DYRK1A Q13627 2/20 0.57
▸ IKBKE Q14164 2/20 0.57
▸ NTRK3 Q16288 2/20 0.57
▸ NTRK2 Q16620 2/20 0.57
▸ LRRK2 Q5S007 2/20 0.57
▸ TAOK1 Q7L7X3 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4115196 0.93 JAK2 (0.70) JAK2JAK1JAK3HDAC6TYK2
SCHEMBL10179928 0.91 JAK2 (0.62) JAK2JAK1JAK3HDAC6TYK2
SCHEMBL13695710 0.91 JAK2 (0.80) JAK2JAK1JAK3HDAC6TYK2
SCHEMBL29540692 0.91 JAK2 (0.64) JAK2JAK1JAK3HDAC6TYK2
SCHEMBL98856 0.91 JAK2 (0.64) JAK2JAK1JAK3HDAC6TYK2
SCHEMBL13695657 0.90 JAK2 (0.72) JAK2JAK1JAK3HDAC6TYK2
SCHEMBL100150 0.90 JAK2 (0.81) JAK2JAK1JAK3HDAC6TYK2
SCHEMBL99812 0.90 JAK2 (0.61) JAK2JAK1JAK3HDAC6TYK2
SCHEMBL171725 0.90 JAK2 (0.66) JAK2JAK1JAK3HDAC6TYK2
SCHEMBL29540937 0.90 JAK2 (0.63) JAK2JAK1JAK3HDAC6TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103254190-A Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors INCYTE CORP 2013-08-21 — — CN claimed
CN-103214483-A Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors INCYTE CORP 2013-07-24 — — CN claimed
CN-103214484-A Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors INCYTE CORP A DELAWARE CORP 2013-07-24 — — CN claimed
CN-101448826-A Heteroaryl substituted pyrrolo [2 ] as janus kinase inhibitors INCYTE CORP (US) 2009-06-03 — — CN claimed
CN-103254190-B Heteroaryl substituted pyrrolo-[2,3-b] pyridine and pyrrolo-[2,3-b] pyrimidine as Janus inhibitors of kinases 因塞特控股公司 2016-12-07 — — CN disclosed
CN-103214484-B Pyrrolo-[2,3-b] pyridine replaced as the heteroaryl of Janus inhibitors of kinases and pyrrolo-[2,3-b] pyrimidine 因塞特控股公司 2016-07-06 — — CN disclosed
CN-103214483-B Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors INCYTE CORP 2014-12-17 — — CN disclosed
US-20140315931-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-10-23 — — US disclosed
US-20140315931-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-10-23 — — US disclosed
US-8741912-B2 Deazapurines useful as inhibitors of Janus kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-06-03 — — US disclosed
US-8741912-B2 Deazapurines useful as inhibitors of Janus kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-06-03 — — US disclosed
CN-103254190-A Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors INCYTE CORP 2013-08-21 — — CN disclosed
CN-103214483-A Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors INCYTE CORP 2013-07-24 — — CN disclosed
US-20120316186-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED 2012-12-13 — — US disclosed
US-20120316186-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED 2012-12-13 — — US disclosed
US-20090227607-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED 2009-09-10 — — US disclosed
US-20090227607-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED 2009-09-10 — — US disclosed
CN-101448826-A Heteroaryl substituted pyrrolo [2 ] as janus kinase inhibitors INCYTE CORP (US) 2009-06-03 — — CN disclosed
US-20090088445-A1 Deazapurines useful as inhibitors of Janus kinases VERTEX PHARMACEUTICALS INCORPORATED 2009-04-02 — — US disclosed
US-20090088445-A1 Deazapurines useful as inhibitors of Janus kinases VERTEX PHARMACEUTICALS INCORPORATED 2009-04-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088445-A1 Deazapurines useful as inhibitors of Janus kinases JAK1, JAK3, JAK2 JAK2 3/4885JAK1 1/4885JAK3 2/4885
US-20140315931-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES JAK1, JAK3, JAK2 JAK2 3/4885JAK1 1/4885JAK3 2/4885
US-20090227607-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES JAK1, JAK3, JAK2 JAK2 3/4885JAK1 1/4885JAK3 2/4885
US-20120316186-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES JAK1, JAK3, JAK2 JAK2 3/4885JAK1 1/4885JAK3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.